These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 8739051)

  • 1. Significance of an abnormal response during pituitary desensitization in an in vitro fertilization and embryo transfer program.
    Goswami SK; Chakravarty BN; Kabir SN
    J Assist Reprod Genet; 1996 May; 13(5):374-80. PubMed ID: 8739051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A study of the controlled ovarian hyperstimulation using GnRH agonist and pure FSH in in vitro fertilization-embryo transfer and gamete intrafallopian transfer program].
    Usui A
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1431-8. PubMed ID: 2511261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success.
    Seifer DB; Thornton KL; DeCherney AH; Lavy G
    Fertil Steril; 1991 Sep; 56(3):500-4. PubMed ID: 1909977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-control study on reduced-dose depot versus daily administration of gonadotrophin-releasing hormone agonists for pituitary desensitization in in vitro fertilization cycles.
    Gao J; Xu YW; Miao BY; Zhou CQ
    J Obstet Gynaecol Res; 2014 Jul; 40(7):1901-6. PubMed ID: 25056469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of controlled ovarian hyperstimulation delayed, which occurs after functionally pituitary downregulation by depot GnRH agonist, on the outcome of in vitro fertilization and embryo transfer].
    Ma QH; Li SW; Huang ZY; Han ZY; Qiu DS; Han DW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Nov; 38(6):980-3. PubMed ID: 18095601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished ovarian reserve is the predominant risk factor for gonadotropin-releasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles.
    Reichman DE; Zakarin L; Chao K; Meyer L; Davis OK; Rosenwaks Z
    Fertil Steril; 2014 Jul; 102(1):99-102. PubMed ID: 24882557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?
    Schmitz C; Bocca S; Beydoun H; Stadtmauer L; Oehninger S
    J Assist Reprod Genet; 2012 Sep; 29(9):877-82. PubMed ID: 22729431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A prospective, randomized controlled study comparing the effects of gonadotropin-releasing hormone agonist long and short protocols for in vitro fertilization].
    Ye H; Huang G; Pei L
    Zhonghua Fu Chan Ke Za Zhi; 2001 Apr; 36(4):222-5. PubMed ID: 11783366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of estradiol/follicle and estradiol/oocyte ratios on the outcome of controlled ovarian stimulation for in vitro fertilization.
    Orvieto R; Zohav E; Scharf S; Rabinson J; Meltcer S; Anteby EY; Homburg R
    Gynecol Endocrinol; 2007 Feb; 23(2):72-5. PubMed ID: 17454155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of basal serum luteinizing hormone and luteinizing hormone/follicle-stimulating hormone ratio on outcomes of in vitro fertilization-embryo transfer in patients with polycystic ovarian syndrome].
    Geng X; Ou X; Liao Y; Tan W; Wang S; Quan S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):857-60. PubMed ID: 23803197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.